| PUBLICATIONS (Ranked by Impact Factor of the Journal) | LABORATORY RESEARCH Synergistic Antitumor Activity of Lapatinib and Retinoids on a Novel Subtype of Breast Cancer with Coamplification of ERBB2 and RARA Here, researchers demonstrate that 23–32% of the human ERBB2+ breast cancers show coamplification of retinoic acid receptor alpha (RARA), encoding the retinoic acid receptor, RARα. [Oncogene] Abstract Trastuzumab Induces Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) in HER-2-Non-Amplified Breast Cancer Cell Lines In this study, researchers investigated the possibility that trastuzumab might induce ADCC against HER-2-non-amplified breast cancer cells. [Ann Oncol] Abstract High Level of miR-21, miR-10b, and miR-31 Expression in Bilateral vs. Unilateral Breast Carcinomas This study suggests that bilateral breast tumors have somewhat distinct patterns of molecular events as compared to the unilateral disease. [Breast Cancer Res Treat] Abstract ERp29 Induces Breast Cancer Cell Growth Arrest and Survival through Modulation of Activation of p38 and Upregulation of ER Stress Protein p58IPK Here, scientists show that endoplasmic reticulum protein 29 (ERp29)-induced cancer cell growth arrest is modulated by the interplay between the concomitant phosphorylation of p38 and upregulation of the inhibitor of the interferon-induced, double-stranded RNA-activated protein kinase, p58IPK. [Lab Invest] Abstract Regulation of CXCL8/IL-8 Expression by Zonula Occludens-1 in Human Breast Cancer Cells Researchers investigated here the influence of zonula occludens-1 on chemokines expression in breast cancer cells. [Mol Cancer Res] Abstract MYC Gene Amplification Is Often Acquired in Lethal Distant Breast Cancer Metastases of Unamplified Primary Tumors Researchers’ observations underscore the importance of MYC in breast cancer progression/metastasis, as well as its relevance as a potential therapeutic target in otherwise incurable metastatic disease. [Mod Pathol] Abstract Mammary Tumors that Become Independent of the Type I Insulin-Like Growth Factor Receptor Express Elevated Levels of Platelet-Derived Growth Factor Receptors These results demonstrate a novel interaction between the insulin-like growth factor receptor and platelet-derived growth factor receptors and highlight an important, therapeutically relevant pathway, for tumor cell migration and invasion. [BMC Cancer] Abstract TBX3 Over-Expression Causes Mammary Gland Hyperplasia and Increases Mammary Stem-Like Cells in an Inducible Transgenic Mouse Model In this study, researchers created doxycycline inducible double transgenic mice (MMTV-rtTA;tet-myc-TBX3-IRES-Luciferase) to test whether T-box transcription factor TBX3 over-expression can induce tumor formation within the mammary gland. [BMC Dev Biol] Abstract CLINICAL RESEARCH RIBBON-2: A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial Evaluating the Efficacy and Safety of Bevacizumab in Combination with Chemotherapy for Second-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer This phase III study compared the efficacy and safety of bevacizumab combined with standard chemotherapy regimens versus chemotherapy alone as second-line treatment of patients with human epidermal growth factor receptor 2–negative metastatic breast cancer. [J Clin Oncol] Abstract A Pilot Study of MUC-1/CEA/TRICOM Poxviral-Based Vaccine in Patients with Metastatic Breast and Ovarian Cancer This study was conducted to obtain preliminary evidence of clinical response in metastatic breast and ovarian cancer patients. [Clin Cancer Res] Abstract | Press Release Early Operable Breast Cancer in Elderly Women Treated with an Aromatase Inhibitor Letrozole as Sole Therapy Scientists studied the outcome of patients treated with letrozole as primary endocrine therapy. [Br J Cancer] Abstract CHEK2*1100delC Homozygosity Is Associated with a High Breast Cancer Risk in Women This study investigated the occurrence of homozygosity for the CHEK2*1100delC allele among familial breast cancer cases and the associated breast cancer risk. [J Med Genet] Abstract |
| SCIENCE NEWS | First Evidence of New ‘Druggable’ DNA Repair Target to Destroy Cancer Cells Researchers have developed small molecules that block APE1. They tested the ability of these molecules to stop the enzyme from repairing DNA damage in breast, pancreatic and cervical cancer cells containing faults in BRCA1 or BRCA2 genes. [Press release from Cancer Research UK discussing research presented at the National Cancer Research Institute Cancer Conference, Liverpool] Press Release |
|
|
|